A phase I study of high-dose topotecan with filgrastim and peripheral blood stem cell support for patients with refractory malignancies
Latest Information Update: 18 Sep 2021
Price :
$35 *
At a glance
- Drugs Topotecan (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 02 Jul 2014 Biomarkers information updated
- 07 Sep 2006 Status change
- 07 Oct 2005 New trial record.